The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation

Silvia Martini; Maria Francesca Donato; Chiara Mazzarelli; Maria Rendina; Ubaldo Visco-Comandini; Daniela Filì; Alice Gianstefani; Stefano Fagiuoli; Mario Melazzini; Simona Montilla; Luca Pani; Sandra Petraglia; Pierluigi Russo; Maria Paola Trotta; Paola Carrai; Paolo Caraceni; ITACOPS study group

doi:10.1111/liv.13588

The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation

Silvia Martini, Maria Francesca Donato, Chiara Mazzarelli, Maria Rendina, Ubaldo Visco-Comandini, Daniela Filì, Alice Gianstefani, Stefano Fagiuoli, Mario Melazzini, Simona Montilla, Luca Pani, Sandra Petraglia, Pierluigi Russo, Maria Paola Trotta, Paola Carrai, Paolo Caraceni, ITACOPS study group

Research output: Contribution to journal › Article

Abstract

BACKGROUND & AIMS: This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program.METHODS: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks.RESULTS: Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for

Original language	English
Journal	Liver International
DOIs	https://doi.org/10.1111/liv.13588
Publication status	Published - Sep 16 2017

Fingerprint

Keywords

Journal Article

Cite this

Martini, S., Donato, M. F., Mazzarelli, C., Rendina, M., Visco-Comandini, U., Filì, D., Gianstefani, A., Fagiuoli, S., Melazzini, M., Montilla, S., Pani, L., Petraglia, S., Russo, P., Trotta, M. P., Carrai, P., Caraceni, P., & group, ITACOPS. S. (2017). The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation. Liver International. https://doi.org/10.1111/liv.13588

The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation. / Martini, Silvia; Donato, Maria Francesca; Mazzarelli, Chiara; Rendina, Maria; Visco-Comandini, Ubaldo; Filì, Daniela; Gianstefani, Alice; Fagiuoli, Stefano; Melazzini, Mario; Montilla, Simona; Pani, Luca; Petraglia, Sandra; Russo, Pierluigi; Trotta, Maria Paola; Carrai, Paola; Caraceni, Paolo; group, ITACOPS study.

In: Liver International, 16.09.2017.

Research output: Contribution to journal › Article

Martini, S, Donato, MF, Mazzarelli, C, Rendina, M, Visco-Comandini, U, Filì, D, Gianstefani, A, Fagiuoli, S, Melazzini, M, Montilla, S, Pani, L, Petraglia, S, Russo, P, Trotta, MP, Carrai, P, Caraceni, P & group, ITACOPSS 2017, 'The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation', Liver International. https://doi.org/10.1111/liv.13588

Martini, Silvia ; Donato, Maria Francesca ; Mazzarelli, Chiara ; Rendina, Maria ; Visco-Comandini, Ubaldo ; Filì, Daniela ; Gianstefani, Alice ; Fagiuoli, Stefano ; Melazzini, Mario ; Montilla, Simona ; Pani, Luca ; Petraglia, Sandra ; Russo, Pierluigi ; Trotta, Maria Paola ; Carrai, Paola ; Caraceni, Paolo ; group, ITACOPS study. / The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation. In: Liver International. 2017.

@article{007d2b44207545fdb78585609b70b99f,

title = "The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation",

abstract = "BACKGROUND & AIMS: This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program.METHODS: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks.RESULTS: Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for ",

keywords = "Journal Article",

author = "Silvia Martini and Donato, {Maria Francesca} and Chiara Mazzarelli and Maria Rendina and Ubaldo Visco-Comandini and Daniela Fil{\`i} and Alice Gianstefani and Stefano Fagiuoli and Mario Melazzini and Simona Montilla and Luca Pani and Sandra Petraglia and Pierluigi Russo and Trotta, {Maria Paola} and Paola Carrai and Paolo Caraceni and group, {ITACOPS study}",

note = "{\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",

year = "2017",

month = sep,

day = "16",

doi = "10.1111/liv.13588",

language = "English",

journal = "Liver International",

issn = "1478-3223",

publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation

AU - Martini, Silvia

AU - Donato, Maria Francesca

AU - Mazzarelli, Chiara

AU - Rendina, Maria

AU - Visco-Comandini, Ubaldo

AU - Filì, Daniela

AU - Gianstefani, Alice

AU - Fagiuoli, Stefano

AU - Melazzini, Mario

AU - Montilla, Simona

AU - Pani, Luca

AU - Petraglia, Sandra

AU - Russo, Pierluigi

AU - Trotta, Maria Paola

AU - Carrai, Paola

AU - Caraceni, Paolo

AU - group, ITACOPS study

PY - 2017/9/16

Y1 - 2017/9/16

N2 - BACKGROUND & AIMS: This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program.METHODS: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks.RESULTS: Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for

AB - BACKGROUND & AIMS: This study aimed to assess the real-life clinical and virological outcomes of HCV waitlisted patients for liver transplantation (LT) who received sofosbuvir/ribavirin (SOF/R) within the Italian compassionate use program.METHODS: Clinical and virological data were collected in 224 patients with decompensated cirrhosis and/or hepatocellular carcinoma (HCC) receiving daily SOF/R until LT or up a maximum of 48 weeks.RESULTS: Of 100 transplanted patients, 51 were HCV-RNA negative for >4 weeks before LT (SVR12: 88%) and 49 negative for

KW - Journal Article

U2 - 10.1111/liv.13588

DO - 10.1111/liv.13588

M3 - Article

JO - Liver International

JF - Liver International

SN - 1478-3223

ER -

Access to Document

10.1111/liv.13588